• TELA Bio Inc TELA.OQ reported a quarterly adjusted loss of 42 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of five analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -44 cents to -31 cents per share.

• Revenue rose 25.9% to $18.96 million from a year ago; analysts expected $18.85 million.

• TELA Bio Inc's reported EPS for the quarter was a loss of 42 cents​.

• The company reported a quarterly loss of $10.37 million.

• TELA Bio Inc shares had risen by 18.2% this quarter and lost 54.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for TELA Bio Inc is $9.00

This summary was machine generated from LSEG data November 9 at 12:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)